Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) | PAR 21 056

Opportunity Information: Apply for PAR 21 056

This funding opportunity (PAR 21-056) is a National Institutes of Health (NIH) cooperative agreement (U01; clinical trial optional) focused on the analytical validation of a single, well-supported candidate biomarker for neurological or neuromuscular diseases and conditions. The core intent is not to discover new biomarkers, but to take a biomarker that already looks promising and subject its measurement method to rigorous, FDA-aligned analytical validation so that results are reproducible, accurate, and dependable across settings. In practical terms, the program is meant to move a biomarker assay from "it seems to work in our lab" to "it performs consistently under defined conditions, with clearly documented performance characteristics," which is what is needed before a biomarker can credibly support clinical research, patient stratification, or future regulatory discussions.

The announcement assumes three major prerequisites are already in place before an application is proposed. First, the candidate biomarker has already been identified with strong supporting rationale and evidence. Second, a detection technology or assay method has already been developed (so the work is not primarily about inventing a new platform from scratch). Third, there is a defined research and/or clinical need and a plausible context of use, meaning applicants should be able to explain how the biomarker measurement is intended to be used (for example, as a pharmacodynamic marker, a disease progression indicator, a patient selection tool, or another well-articulated use case), even if full clinical validation is not the focus at this stage.

The technical emphasis is on analytical validation of the biomarker measurement method. That includes characterizing the detection method and its performance characteristics, and systematically identifying the conditions that optimize accuracy and reproducibility. Although the opportunity text does not list every parameter explicitly, the phrase "consistent with FDA guidelines" signals expectations typical of analytical validation work: establishing assay precision and reproducibility (within-run, between-run, between-operator, and potentially between-site), accuracy or trueness where reference materials exist, analytical sensitivity and limits of detection/quantification, analytical specificity and interference testing, linearity and dynamic range, stability of samples and reagents, robustness to small procedural variations, and clear quality control and acceptance criteria. A strong application would usually translate these general expectations into a concrete validation plan, including standardized operating procedures, pre-specified performance targets, and a strategy for documenting and reporting results in a way that others can replicate.

Because the mechanism is a cooperative agreement (U01), awardees should generally expect substantial NIH programmatic involvement compared with a standard research grant. Cooperative agreements commonly involve active coordination with NIH staff on milestones, data and method standardization, and progress oversight. The "clinical trial optional" designation means a clinical trial is not required, but applicants may include clinical study elements if they are needed to support the analytical validation objectives (for example, using clinical specimens to test assay performance across relevant patient populations), provided the proposed work fits NIH definitions and requirements.

Eligibility is broad across U.S.-based organizations and includes state, county, and local governments; special district governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; Native American tribal governments (federally recognized); tribal organizations (other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The announcement also highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and Indian/Native American Tribal Governments other than federally recognized entities.

Foreign involvement is explicitly restricted. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply, non-domestic components of U.S. organizations are not eligible to apply, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed. In other words, applications must be fully domestic in organizational scope and performance sites, consistent with the stated policy limits.

Administratively, this is a discretionary funding opportunity in the health category under CFDA number 93.853, run by NIH. The opportunity was created on 2020-11-19, and the original closing date listed is 2023-09-07. The posted excerpt does not provide an award ceiling or the expected number of awards, so applicants would typically need to consult the full NIH notice or related institute-specific guidance for budget expectations, project period norms, and any institute priorities tied to neurological or neuromuscular disorders.

Overall, the best fit for this program is a team that already has a compelling biomarker and an existing assay approach, and now needs structured, FDA-consistent analytical validation work to lock down reliability, define operating conditions, and produce a measurement method that the broader field can trust for downstream clinical research and potential future qualification efforts.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853.
• This funding opportunity was created on 2020-11-19.
• Applicants must submit their applications by 2023-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 21 056

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: